Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 541

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 2
Chunk 541
---
    (6)

    —

    75,000

    —

    1.105

    10/09/34

(1)
The options have a seven-year term or ten-year term as noted in the table subject to earlier expiration upon termination.

(2)
The options vest over a period of three years from August 4, 2021, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending August 4, 2024.

(3)
The options vest over a period of three years from January 26, 2022, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending January 26, 2025.

(4)
The options vest over a period of three years from January 18, 2023, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending January 18, 2026.

(5)
The options vest over a period of three years from January 22, 2024, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending January 18, 2027.

(6)
The options vest over a period of three years from October 9, 2024, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending October 9, 2027.

(7)
The options vest over a period of three years from August 7, 2023, 33.3% on the first anniversary of such date and 8.33% every three
months thereafter, ending August 7, 2026.

84

Employment
Agreements and Potential Payments on Employment Termination

Set
forth below is a description of the employment agreements with our named executive officers and a summary of the benefits that would
be payable upon termination of employment or in connection with a change in control to our named executive officers under their employment
agreements with us.

Jeffrey
A. Meckler

We
have entered into an employment agreement with Jeffrey A. Meckler (the “Meckler Employment Agreement”), which superseded
and replaced his employment agreement dated December 11, 2017 with Intec Pharma, Inc., a subsidiary of Intec Israel, to serve